Suvorexant (MK-4305)

Alias: MK4305; MK 4305; MK-4305

Cat No.:V1306 Purity: ≥98%

COA Product Data Instructions for use SDS

Suvorexant (MK-4305) Chemical Structure CAS No.: 1030377-33-3
Product category: OX Receptor

This product is for research use only, not for human use. We do not sell to patients.

Size	Price	Stock	Qty
5mg
10mg
25mg

ADD TO CART CHECKOUT BULK INQUIRY

1-708-310-1919 sales@invivochem.com

Official Supplier of:

Business Relationship with 5000+ Clients Globally
Major Universities, Research Institutions, Biotech & Pharma
Citations by Top Journals: Nature, Cell, Science, etc.

Top Publications Citing lnvivochem Products

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

Purity & Quality Control Documentation

Current batch：

Purity: ≥98%

COA

MSDS

NMR

Instructions

Product Description
Bioactivity & Protocols
Physicochemical Properties
Solubility Data
Calculators
Clinical Trial Information
Biological Data

Product Description

This is a DEA controlled substance schedule IV Suvorexant (also known as MK-4305) is a potent dual OX receptor antagonist with Ki of 0.55 nM and 0.35 nM for OX1 receptor and OX2 receptor, respectively. Suvorexant is a medication that Merck is developing to treat insomnia. Phase III trials are presently being conducted on it. Suvorexant functions by inhibiting wakefulness as opposed to promoting sleep. Suvorexant (MK-4305), a dual orexin receptor (OXR) antagonist (DORA), has demonstrated potential in the treatment of insomnia and sleep disorders.

Biological Activity I Assay Protocols (From Reference)

ln Vitro

In vitro activity: Suvorexant, also referred to as MK-4305, is a strong antagonist of both OX1 and OX2 receptors, with Ki values of 0.55 nM and 0.35 nM, respectively. Merck is the company that developed suvorexant to treat insomnia. Phase III trials are presently being conducted on it. Suvorexant functions by inhibiting wakefulness as opposed to promoting sleep. Suvorexant (MK-4305), a dual orexin receptor (OXR) antagonist (DORA), has demonstrated potential in the treatment of insomnia and sleep disorders.

ln Vivo

Suvorexant (25 mg/kg) was tested in mice during the inactive phase (lights on), when sleep is more common and orexin levels are typically low, in an in-vivo study. Suvorexant was found to significantly alter the architecture of sleep by increasing REM specifically during the first four hours after dosage. Suvorexant only considerably reduced wake at the tested doses for the first hour, while IPSU had no effect on wake time. These findings imply that, in contrast to DORAs, OX2R preferring antagonists may have a reduced propensity to disturb NREM/REM architecture.

Enzyme Assay

MK-4305 possesses a Ki value of 0.55 nM for OX1 receptor and 0.35 nM for OX2 receptor, making it a strong antagonist of both receptors.

Cell Assay

Based on an MDS Pharma off-target screen of 170 enzymes, receptors, and ion channels, an in vitro investigation revealed that MK-4305 had a clean ancillary profile (>10000-fold selectivity for OX2R).

Animal Protocol

N/A

Mice

References

[1]. J Med Chem . 2010 Jul 22;53(14):5320-32.

[2]. Br J Pharmacol . 2014 Jan;171(2):351-63.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Physicochemical Properties

Molecular Formula

C23H23CLN6O2

Molecular Weight

450.92

Exact Mass

450.16

CAS #

1030377-33-3

Related CAS #

1030377-33-3

SMILES

C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl

InChi Key

JYTNQNCOQXFQPK-MRXNPFEDSA-N

InChi Code

InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1

Chemical Name

[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone

Synonyms

MK4305; MK 4305; MK-4305

Storage

Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility Data

Solubility (In Vitro)

DMSO: ~10 mg/mL (~22.2 mM)

Water: <1 mg/mL

Ethanol: <1 mg/mL

Solubility (In Vivo)

4% DMSO+10% PEG 400+10% Tween 80: 5mg/mL

(Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.2177 mL	11.0884 mL	22.1769 mL
	5 mM	0.4435 mL	2.2177 mL	4.4354 mL
	10 mM	0.2218 mL	1.1088 mL	2.2177 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Mass

Concentration

Volume

Molecular Weight*

Calculate Reset

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

Calculate the Mass of a compound required to prepare a solution of known volume and concentration
Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume

See Example

An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?

Enter 350.26 in the Molecular Weight (MW) box
Enter 10 in the Concentration box and choose the correct unit (mM)
Enter 5 in the Volume box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Concentration (Start)

Volume (Start)

Concentration (End)

Volume (End)

Calculate Reset

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:

Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
Enter 25 into the Concentration (End) box and select the correct unit (mM)
Enter 25 into the Volume (End) box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box

Molecular formula

Total molecular weight

g/mol

Calculate Reset

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4 c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Calculate Reset

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
Click the “Calculate” button
The answer appears in the Volume (to add to vial) box

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)

Dosage mg/kg

Average weight of animals g

Dosing volume per animal μL

Number of animals

Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)

% DMSO

% Tween 80

% ddH₂O

Calculate Reset

Calculation results

Working concentration： mg/mL；

Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O，mix and clarify.

Note： (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05145764	Recruiting	Drug: Suvorexant Drug: Placebo	Suvorexant Placebo Opioid Use Disorder	Johns Hopkins University	March 30, 2022	Phase 2
NCT05656534	Recruiting	Drug: Suvorexant Drug: Placebo	Alcohol Use Disorder	Ohio State University	November 29, 2022	Early Phase 1
NCT05733286	Recruiting	Drug: Suvorexant 20 mg Drug: Placebo	Delirium in Old Age	Duke University	June 28, 2023	Phase 2
NCT05593653	Recruiting	Drug: Suvorexant Drug: Placebo	Insomnia Diabetes	Brigham and Women's Hospital	January 6, 2023	Phase 4
NCT04262193	Recruiting	Drug: Suvorexant Drug: Suvorexant Placebo	Sleep Opioid-use Disorder	Wayne State University	February 1, 2021	Phase 2

Biological Data